Advertisement

Drug Safety

, Volume 41, Issue 8, pp 817–826 | Cite as

Use of Proton Pump Inhibitors and the Risk of Acute Kidney Injury Among Patients with Rheumatoid Arthritis: Cohort Study

  • Henrik Svanström
  • Marie Lund
  • Mads Melbye
  • Björn Pasternak
Original Research Article

Abstract

Introduction

Recent observational studies have indicated that use of proton pump inhibitors may be associated with adverse renal outcomes. The objective of this study was to investigate whether the use of proton pump inhibitors increases the risk of acute kidney injury among patients with rheumatoid arthritis.

Methods

We conducted the study as a historical prospective cohort study, including patients with rheumatoid arthritis, 30–84 years of age, during 2004–2015. Among these, we identified and matched episodes of use and non-use of proton pump inhibitors (control episodes) 1:4 on the propensity score, including 24,579 episodes of use of proton pump inhibitors and 98,230 control episodes. The primary outcome was a first diagnosis of acute kidney injury and the secondary outcome was any serious renal event (acute kidney injury or chronic kidney disease). The primary time point for analysis was 120 days after study entry.

Results

The incidence rate of acute kidney injury was 2.2 per 1000 person-years during episodes of use of proton pump inhibitors and 0.9 during control episodes. Use of proton pump inhibitors was associated with a significantly increased risk of acute kidney injury (hazard ratio 2.30, 95% confidence interval 1.26–4.20). The absolute risk difference was 40 (95% confidence interval 8–99) events of acute kidney injury per 100,000 episodes of use of proton pump inhibitors. Use of proton pump inhibitors was also associated with a significantly increased risk of the secondary outcome of any serious renal event (hazard ratio 2.61, 95% confidence interval 1.80–3.80).

Conclusions

This cohort study among patients with rheumatoid arthritis found a significantly increased risk of acute kidney injury associated with the use of proton pump inhibitors. These findings may help inform clinical decision making when considering the risks and benefits of proton pump inhibitor treatment in rheumatoid arthritis.

Notes

Compliance with Ethical Standards

Funding

The study was supported by Lundbeck Foundation Grant no. R219-2016-270 (Dr. Svanström). Dr. Pasternak was supported by an investigator grant from the Strategic Research Area Epidemiology Program at Karolinska Institutet. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Conflicts of interest

Henrik Svanström, Mads Melbye, and Björn Pasternak have no conflicts of interest directly relevant to the content of this study. Marie Lund reports personal fees from Dansk Lægemiddel Information A/S, outside the submitted work.

Ethics approval

The study was approved by the Danish Data Protection Agency. Ethics approval is not required for register-based research in Denmark.

Data availability

No additional material or data available.

Supplementary material

40264_2018_663_MOESM1_ESM.pdf (78 kb)
Supplementary material 1 (PDF 77 kb)

References

  1. 1.
    Scarpignato C, Gatta L, Zullo A, Blandizzi C, SIF-AIGO-FIMMG Group, Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists and the Italian Federation of General Practitioners. Effective and safe proton pump inhibitor therapy in acid-related diseases: a position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14(1):179.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    National Institute for Health and Care Excellence. 2009 updated 2015. Rheumatoid arthritis in adults: management [CG79]. https://www.nice.org.uk/guidance/cg79. Accessed 24 Aug 2017.
  3. 3.
    Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336(7634):2–3.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Heidelbaugh JJ, Kim AH, Chang R, Walker PC. Overutilization of proton-pump inhibitors: what the clinician needs to know. Ther Adv Gastroenterol. 2012;5(4):219–32.CrossRefGoogle Scholar
  5. 5.
    Schoenfeld AJ, Grady D. Adverse effects associated with proton pump inhibitors. JAMA Intern Med. 2016;176(2):172–4.CrossRefPubMedGoogle Scholar
  6. 6.
    Lee J, Mark RG, Celi LA, Danziger J. Proton pump inhibitors are not associated with acute kidney injury in critical illness. J Clin Pharmacol. 2016;56(12):1500–6.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Leonard CE, Freeman CP, Newcomb CW, Reese PP, Herlim M, Bilker WB, et al. Proton pump inhibitors and traditional nonsteroidal anti-inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury. Pharmacoepidemiol Drug Saf. 2012;21(11):1155–72.CrossRefPubMedGoogle Scholar
  8. 8.
    Antoniou T, Macdonald EM, Hollands S, Gomes T, Mamdani MM, Garg AX, et al. Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study. CMAJ Open. 2015;3(2):E166–71.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Klatte DCF, Gasparini A, Xu H, de Deco P, Trevisan M, Johansson ALV, et al. Association between proton pump inhibitor use and risk of progression of chronic kidney disease. Gastroenterology. 2017;153(3):702–10.CrossRefPubMedGoogle Scholar
  10. 10.
    Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238–46.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol. 2016;27(10):3153–63.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Hickson LJ, Crowson CS, Gabriel SE, McCarthy JT, Matteson EL. Development of reduced kidney function in rheumatoid arthritis. Am J Kidney Dis. 2014;63(2):206–13.CrossRefPubMedGoogle Scholar
  13. 13.
    Karie S, Gandjbakhch F, Janus N, Launay-Vacher V, Rozenberg S, Mai Ba CU, et al. Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study. Rheumatology. 2007;47(3):350–4.CrossRefGoogle Scholar
  14. 14.
    Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014;37(4):201–11.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Moledina DG, Perazella MA. PPIs and kidney disease: from AIN to CKD. J Nephrol. 2016;29(5):611–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–90.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Helweg-Larsen K. The Danish Register of causes of death. Scand J Public Health. 2011;39(7 Suppl.):26–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, Sørensen HT, Hallas J, Schmidt M. Data resource profile: the Danish National Prescription Registry. Int J Epidemiol. 2017;46(3):798-798f.PubMedGoogle Scholar
  19. 19.
    The Danish Health Data Authority. Medstat.dk. http://medstat.dk/en. Accessed 24 Aug 2017.
  20. 20.
    Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Brookhart MA, Wyss R, Layton JB, Stürmer T. Propensity score methods for confounding control in nonexperimental research. Circ Cardiovasc Qual Outcomes. 2013;6(5):604–11.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Parsons LS. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. In: Proceedings of the 26th Annual SAS Users Group International Conference. California: Long Beach Convention Center; 2001. p. 214–6.Google Scholar
  23. 23.
    D’Agostino RB, Rubin DB. Estimating and using propensity scores with partially missing data. J Am Stat Assoc. 2000;95(451):749–59.CrossRefGoogle Scholar
  24. 24.
    Naughton CA. Drug-induced nephrotoxicity. Am Fam Physician. 2008;78(6):743–50.PubMedGoogle Scholar
  25. 25.
    Klepser DG, Collier DS, Cochran GL. Proton pump inhibitors and acute kidney injury: a nested case-control study. BMC Nephrol. 2013;14(1):150.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Blank M-L, Parkin L, Paul C, Herbison P. A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int. 2014;86(4):837–44.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Praga M, González E. Acute interstitial nephritis. Kidney Int. 2010;77(11):956–61.CrossRefPubMedGoogle Scholar
  28. 28.
    Härmark L, Van Der Wiel HE, De Groot MCH, Van Grootheest AC. Proton pump inhibitor-induced acute interstitial nephritis. Br J Clin Pharmacol. 2007;64(6):819–23.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Epidemiology ResearchStatens Serum InstitutCopenhagen SDenmark
  2. 2.Department of Clinical MedicineUniversity of CopenhagenCopenhagenDenmark
  3. 3.Department of MedicineStanford University School of MedicineStanfordUSA
  4. 4.Clinical Epidemiology Unit, Department of Medicine SolnaKarolinska InstitutetStockholmSweden

Personalised recommendations